

Fertilizer Sector Update

Climb in Urea and DAP Offtake Recorded for Feb: Up by 8% and 17% Respectively Over SPLY

Fertilizer Landscape

The latest figures released by the National Fertilizer Development Centre (NFDC) shed light on the fertilizer market dynamics for February 2024, a pivotal period marking the penultimate month of the ongoing Rabi season in Pakistan. The data underscores a notable uptick in Urea and DAP offtake, registering respective volumes of 543kT and 115kT, reflecting robust year-on-year growth rates of 8% and 17% compared to February 2023. However, compared to January 2024, there was a slight drop of 11% in Urea offtake, while DAP soared by an impressive 72%.

Total domestic fertilizer production during the month was 776kT. Urea and DAP production was 550kT and 72kT, respectively. Total imported supplies were 90kT that comprised of mainly DAP imports of 71.8kT.

February's closing inventory notably surpassed the recommended buffer stock level of 200kT by a significant 70kT margin, reflecting a healthy market balance. Going-forward, the NFDC expects no imports to take place in the concluding month of the Rabi season, i.e. March 2024. Projections for Urea production stand at 539kT, with an offtake of 481kT expected. Meanwhile, for DAP, supply (domestic production and imports) is forecasted at 100kT, with an offtake of 92kT.

	Feb-24	Feb-23	Y/Y	Jan-24	M/M
Off-take (kt)					
Urea	543	503	8%	613	-11%
DAP	115	98	18%	67	73%
Retail price (PKR/bag)					
Urea	4,691	2,900	62%	4,602	2%
DAP	12,399	10,434	19%	12,755	-3%

Source: NFDC & HMFS Research

Major Players


As the crop cycle nears its conclusion, a predictable pattern emerges wherein farmers curtail their fertilizer application. Consequently, there is a discernible downturn in fertilizer production during these transitional months. In February, notable urea producers such as EFERT and FFC marginally reduced their production outputs by 10% and 8% respectively, aligning with the reduced demand. Despite this adjustment, both industry leaders maintained robust offtake figures, successfully selling the majority of their produced volumes during the month. EFERT retained a market share of 35%, while FFC secured 36% of the urea market share, affirming their competitive positions within the industry.

52-Week High 52-Week Low Current Price (PKR)

	52-Week High	52-Week Low	Current Price (PKR)
FFC	124.00	90.97	121.63
FFBL	32.43	11.11	25.23
EFERT	148.18	75.37	144.91
FATIMA	38.14	26.71	38.14

Source: PSX & HMFS Research

Urea Market Share - February 2024



- FFC
- EFERT
- Fatima
- Dawood
- FFBL
- Others

Source: NFDC & HMFS Research

Rubeya Rashid

rubeya.rashid@hmfs.com.pk

Fertilizer Sector Update

Thursday, March 21, 2024

Climb in Urea and DAP Offtake Recorded for Feb: Up by 8% and 17% Respectively Over SPLY

Some intriguing developments observed during the month were; despite EFERT's overall offtake reducing, there was a noteworthy surge in offtake within the provincial segment of Baluchistan, nearly doubling from January '24 to February '24 (Jan '24: 995T and Feb '24: 2,960T). Conversely, for FFC, the provincial segment of KP witnessed a notable increase of 62.5% in offtakes (Jan '24: 11.6kT and Feb '24: 18.8kT), marking a substantial uptick in demand within this specific region.

Future Prospects

In response to the recent escalation in gas prices to PKR 1,597/mmbtu, EFERT has implemented a corresponding increase in its Urea prices by PKR 882 per bag, raising them to PKR 4,649 per bag. However, given the pending adjustment of gas prices on the Mari network, FFC is expected to follow suit in raising its prices to offset the anticipated rise in production costs. It's noteworthy that the gas price hike will impact 100% of FFC's production, as all of its fertilizer facilities operate on the Mari network. In contrast, EFERT's largest plant, EnVen (with a capacity of 1.3mn MT), operates on the Sui network, while its significant 'Base-plant' (975kMT) is situated on the Mari network. As the agreements for the networks are set to expire in June '24, it's likely that Mari prices will undergo an upward adjustment, resulting in increased input costs for major fertilizer producers. Consequently, this could lead to a rise in their bottom line, attributable to higher revenue collection.

Going-forward, given that the final crop month primarily entails crop harvesting rather than cultivation, we anticipate a decline in both urea production and offtake. Urea production is expected to reach ~540kT, with offtakes projected at ~480kT. In contrast, DAP production is likely to experience an upswing to compensate for the notably low production observed in January '24 (29kT), attributable to delays in the shipment of phosphoric acid due to conflicts in the Middle East. Following the restoration of production to normal levels in February '24 (72kT), we anticipate a sustained production volume of approximately ~75kT in the upcoming month of March '24, despite an anticipated decrease in offtake due to the cyclical nature of fertilizer application.

Urea Industry Volumetric Position

Urea	Feb-24	Feb-23	Y/Y	Jan-24	M/M
Opening Inventory	264	101	161%	105	151%
Production	550	455	21%	600	-8%
Imports	-	-	0%	173	-100%
Off-take	543	503	8%	613	-11%
Closing inventory	270	54	400%	264	2%

Source: NFDC & HMFS Research

	2MCY24	2MCY23	Y/Y
--	--------	--------	-----

Off take (kt)


Urea	1,156	1,134	2%
DAP	182	193	-6%

Avg. retail price (PKR)/bag

Urea	4,647	2,825	64%
DAP	12,577	10,079	25%

Source: NFDC & HMFS Research

Price Performance Relative to KSE-100



Source: PSX & HMFS Research

Disclaimer

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by Habib Metropolitan Financial Services (HMFS) from publicly available information and sources that HMFS believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of HMFS gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of HMFS has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of HMFS. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of HMFS and/or their respective principals, directors, officers, and employees and their families may own, have positions or affect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physical and legal, may be restricted from dealing in the securities market of Pakistan. Investors should perform their own due diligence before investing. No part of the compensation of the authors of this research report was, is or will be directly or indirectly related to the specific recommendations or views contained in the research report. By accepting this research report, you agree to be bound by the foregoing limitations.

HMFS and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. HMFS prohibits its research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis. Furthermore, it is stated that the research analyst (s) or their close relatives have neither served as a director/officer in the past 3 years nor have received any compensation from the subject company in the past 12 months. Additionally, as per regulation 8(2)(i) of the Research Analyst Regulations, 2015, research analysts currently do not have a financial interest in the securities of the subject company aggregating more than 1% of the value of the company. The research analyst(s) also certifies that any spouse(s) or dependents (if relevant) do not hold a beneficial interest in the securities that are subject of this report.

HMFS endeavors to make all reasonable efforts to disseminate its publication to all eligible clients in a timely manner through either physical or electronic distribution such as mail, fax and/or email. Nevertheless, not all clients may receive the material at the same time.

HMFS Stock Ratings System

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. HMFS uses a three tier rating system: i) Buy, ii) Hold and iii) Sell with our rating being based on total stock returns. A table presenting HMFS' rating definitions is given below:

Valuation Methodology

To arrive at our fair value estimates, HMFS uses different valuation methodologies including but not limited to:

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)

HMFS RATING GUIDE

<i>BUY</i>	<i>More than 15% Upside</i>
<i>HOLD</i>	<i>Between 15% Upside & 15% Downside</i>
<i>SELL</i>	<i>More than 15% Downside</i>

Note: All fair value estimates are for a twelve month time horizon unless specified otherwise in the report
Upside/Downside represents the difference between the stated "Fair Value" & the prevailing "Market Price"
Total Return is based on both the Capital Gains return & the Dividend Yield & is exclusive of all applicable taxes